Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Understanding the tumour micro-environment – the pharmaphorum podcast

Health Innovators – Anthony Yanni Part One

Rebranded Servier eyes €3bn in cancer drug sales by 2030

Click and bio-orthogonal chemistry take Nobel Prize 2022

NHS seeks digital solution for “treatment gap” in mental health

Zealand Pharma

zealand pharma

News/ News/ R&D

Positive phase 3 results for Zealand Pharma’s glepaglutide

Nicole Raleigh gastrointestinal disorders, glepaglutide, SBS, short bowel syndrome, Zealand Pharma 0 Comment

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase

X

Positive phase 3 results for Zealand Pharma’s glepaglutide

https://pharmaphorum.com/news/positive-phase-3-results-for-zealand-pharmas-glepaglutide/

Alexion

News/ News/ R&D/ Top stories

Alexion signs R&D deals with two Nordic biotechs

Richard Staines Affibody, Alexion, Rare diseases, Zealand Pharma 0 Comment

Alexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs.

X

Alexion signs R&D deals with two Nordic biotechs

https://pharmaphorum.com/news/alexion-signs-rd-deals-with-two-nordic-biotechs/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3
AstraZeneca pays record 660% premium for gene editing company LogicBio
Roche gets FDA approval for HER2 breast cancer diagnostic
Novo Nordisk achieve headline results with icodec insulin
Sanofi wagers $400m on miRecule muscular dystrophy therapy

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com